Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015:16:516.
doi: 10.1186/s10194-015-0516-6. Epub 2015 Apr 3.

Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial

Charly Gaul  1 , Hans-Christoph Diener, Ulrich Danesch; Migravent® Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial

Charly Gaul et al. J Headache Pain. 2015.

Abstract

Background: Non-medical, non-pharmacological and pharmacological treatments are recommended for the prevention of migraine. The purpose of this randomized double-blind placebo controlled, multicenter trial was to evaluate the efficacy of a proprietary nutritional supplement containing a fixed combination of magnesium, riboflavin and Q10 as prophylactic treatment for migraine.

Methods: 130 adult migraineurs (age 18 - 65 years) with ≥ three migraine attacks per month were randomized into two treatment groups: dietary supplementation or placebo in a double-blind fashion. The treatment period was 3 months following a 4 week baseline period without prophylactic treatment. Patients were assessed before randomization and at the end of the 3-month-treatment-phase for days with migraine, migraine pain, burden of disease (HIT-6) and subjective evaluation of efficacy.

Results: Migraine days per month declined from 6.2 days during the baseline period to 4.4 days at the end of the treatment with the supplement and from 6.2.days to 5.2 days in the placebo group (p = 0.23 compared to placebo). The intensity of migraine pain was significantly reduced in the supplement group compared to placebo (p = 0.03). The sum score of the HIT-6 questionnaire was reduced by 4.8 points from 61.9 to 57.1 compared to 2 points in the placebo-group (p = 0.01). The evaluation of efficacy by the patient was better in the supplementation group compared to placebo (p = 0.01).

Conclusions: Treatment with a proprietary supplement containing magnesium, riboflavin and Q10 (Migravent® in Germany, Dolovent® in USA) had an impact on migraine frequency which showed a trend towards statistical significance. Migraine symptoms and burden of disease, however, were statistically significantly reduced compared to placebo in patients with migraine attacks.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Consort diagram showing recruitment and flow of participants through trial.
See this image and copyright information in PMC

References

    1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med. 2002;346:257–270. doi: 10.1056/NEJMra010917. - DOI - PubMed
    1. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–1345. doi: 10.1212/WNL.0b013e3182535d20. - DOI - PMC - PubMed
    1. Diener HC, Evers S, Förderreuther S, Freilinger T, Fritsche G, Gaul C, Göbel H, Haag G, Heinze A, Holle D, Jürgens T, Katsarava Z, Kropp P, Limmroth V, Malzacher R, Marziniak M, May A, Meier U, Obermann M, Ruschewya R, Straube A, Sandor P, Gantenbein A, Lampl C, Brössner G. Therapie der Migräne. In: Diener HC, Weimar C, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch C-W, Weller M, editors. Leitlinien für Diagnostik und Therapie in der Neurologie, 5th edn. Stuttgart: Thieme; 2012. pp. 688–717.
    1. Tfelt-Hansen PC. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2013;26:869–870. doi: 10.1212/01.wnl.0000427909.23467.39. - DOI - PubMed
    1. Diener HC, Danesch U. Wirksamkeit chemischer, pflanzlicher und diätetischer Migräneprophylaktika. MMW Fortschr Med. 2009;151:42–45. - PubMed

Publication types

MeSH terms